Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2

Cancer Discovery

Volumn 3, Issue 12, 2013, Pages 1378-1393

  O'Connell, Michael P ^a   Marchbank, Katie ^a   Webster, Marie R ^a   Valiga, Alexander A ^a   Kaur, Amanpreet ^a   Vultur, Adina ^a   Li, Ling ^a   Herlyn, Meenhard ^a   Villanueva, Jessie ^a   Liu, Qin ^a   Yin, Xiangfan ^a   Widura, Sandy ^a   Nelson, Janelle ^a   Ruiz, Nivia ^a   Camilli, Tura C ^d   Indig, Fred E ^d   Flaherty, Keith T ^e   Wargo, Jennifer A ^e   Frederick, Dennie T ^e   Cooper, Zachary A ^e   Nair, Suresh ^c   Amaravadi, Ravi K ^b   Schuchter, Lynn M ^b   Karakousis, Giorgos C ^b   Xu, Wei ^b   Xu, Xiaowei ^b   Weeraratna, Ashani T ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LEHIGH VALLEY HOSPITAL   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL) MALEIMIDE; BETA CATENIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N [3 (5 CHLORO 1H PYRROLO [2, 3 B] PYRIDINE 3 CARBONYL) 2, 4 DIFLUOROPHENYL] PROPANESULFONAMIDE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VEMURAFENIB; WNT5A PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; ARTIFICIAL SKIN; BIOTINYLATION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THERAPY RESISTANCE; TUMOR SPHEROID; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM METASTASIS; PHENOTYPE; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SULFONAMIDES; WNT SIGNALING PATHWAY;

EID: 84890063283     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0005     Document Type: Article

References (51)

1. Ghislin S, Deshayes F, Middendorp S, Boggetto N, Alcaide-Loridan C. PHF19 and Akt control the switch between proliferative and invasive states in melanoma. Cell Cycle 2012; 11: 1634-45.
2. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006; 19: 290-302.
3. Dissanayake SK, Olkhanud PB, O'Connell MP, Carter A, French AD, Camilli TC, et al. Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res 2008; 68: 10205-14.
4. Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, Hofman P, et al. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 2011; 30: 2307-18.
5. Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 2012; 31: 2461-70.
6. Widmer DS, Hoek KS, Cheng PF, Eichhoff OM, Biedermann T, Raaijmakers MI, et al. Hypoxia contributes to melanoma heterogeneity by triggering HIF1alpha-dependent phenotype switching. J Invest Dermatol 2013; 133: 2436-43.
7. Goodall J, Martinozzi S, Dexter TJ, Champeval D, Carreira S, Larue L, et al. Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. Mol Cell Biol 2004; 24: 2915-22.
8. Delmas V, Beermann F, Martinozzi S, Carreira S, Ackermann J, Kumasaka M, et al. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 2007; 21: 2923-35.
9. Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, et al. beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011; 20: 741-54.
10. Gallagher SJ, Rambow F, Kumasaka M, Champeval D, Bellacosa A, Delmas V, et al. Beta-catenin inhibits melanocyte migration but induces melanoma metastasis. Oncogene 2013; 32: 2230-8.
11. Grossmann AH, Yoo JH, Clancy J, Sorensen LK, Sedgwick A, Tong Z, et al. The small GTPase ARF6 stimulates b-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci Signal 2013; 6: ra14.
12. Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 2005; 11: 8606-14.
13. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 2009; 106: 1193-8.
14. Arozarena I, Bischof H, Gilby D, Belloni B, Dummer R, Wellbrock C. In melanoma, beta-catenin is a suppressor of invasion. Oncogene 2011; 30: 4531-43.
15. Lee DJ, Kang DH, Choi M, Choi YJ, Lee JY, Park JH, et al. Peroxiredoxin-2 represses melanoma metastasis by increasing E-cadherin/betacatenin complexes in adherens junctions. Cancer Res 2013; 73: 4744-57.
16. Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG, et al. Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAF V600E in human melanoma. Sci Signal 2012; 5: ra3.
17. Webster MR, Weeraratna AT. A Wnt-er migration: the confusing role of beta-catenin in melanoma metastasis. Sci Signal 2013; 6: pe11.
18. Da Forno PD, Pringle JH, Hutchinson P, Osborn J, Huang Q, Potter L, et al. WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res 2008; 14: 5825-32.
19. Dissanayake SK, Wade M, Johnson CE, O'Connell MP, Leotlela PD, French AD, et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 2007; 282: 17259-71.
20. Jenei V, Sherwood V, Howlin J, Linnskog R, Safholm A, Axelsson L, et al. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci U S A 2009; 106: 19473-8.
21. O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 2010; 29: 34-44.
22. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1: 279-88.
23. Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/ JNK signalling pathway. Genes Cells 2003; 8: 645-54.
24. Katoh M. Comparative genomics on ROR1 and ROR2 orthologs. Oncol Rep 2005; 14: 1381-4.
25. Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 1992; 267: 26181-90.
26. Bicocca VT, Chang BH, Kharabi Masouleh B, Muschen M, Loriaux MM, Druker BJ, et al. Crosstalk between ROR1 and the pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012; 22: 656-67.
27. Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 2012; 21: 348-61.
28. Cui B, Zhang S, Chen L, Yu J, Widhopf GF II, Fecteau JF, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res 2013; 73: 3649-60.
29. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS ONE 2012; 7: e31127.
30. Hojjat-Farsangi M, Ghaemimanesh F, Daneshmanesh AH, Bayat AA, Mahmoudian J, Jeddi-Tehrani M, et al. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells. PLoS ONE 2013; 8: e61167.
31. Berking C, Herlyn M. Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology. Histol Histopathol 2001; 16: 669-74.
32. Amaravadi RK, Winkler JD. Lys05: a new lysosomal autophagy inhibitor. Autophagy 2012; 8: 1383-4.
33. Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK. Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 2010; 46: 1159-69.
34. Wright TM, Rathmell WK. Identification of Ror2 as a hypoxiainducible factor target in von Hippel-Lindau-associated renal cell carcinoma. J Biol Chem 2010; 285: 12916-24.
35. Feige E, Yokoyama S, Levy C, Khaled M, Igras V, Lin RJ, et al. Hypoxiainduced transcriptional repression of the melanoma-associated oncogene MITF. Proc Natl Acad Sci U S A 2011; 108: E924-33.
36. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, Yang Y. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 2003; 162: 899-908.
37. Nakayama K, Qi J, Ronai Z. The ubiquitin ligase Siah2 and the hypoxia response. Mol Cancer Res 2009; 7: 443-51.
38. Qi J, Nakayama K, Gaitonde S, Goydos JS, Krajewski S, Eroshkin A, et al. The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and-independent pathways. Proc Natl Acad Sci U S A 2008; 105: 16713-8.
39. Eichhoff OM, Weeraratna A, Zipser MC, Denat L, Widmer DS, Xu M, et al. Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res 2011; 24: 631-42.
40. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18: 683-95.
41. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/ cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999; 154: 325-9.
42. Takeda K, Yasumoto K, Takada R, Takada S, Watanabe K, Udono T, et al. Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J Biol Chem 2000; 275: 14013-6.
43. Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward R, Viros A, et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 2011; 19: 45-57.
44. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008; 14: 396-404.
45. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res 2011; 71: 3132-41.
46. Rabbani H, Ostadkarampour M, Danesh Manesh AH, Basiri A, Jeddi-Tehrani M, Forouzesh F. Expression of ROR1 in patients with renal cancer-a potential diagnostic marker. Iran Biomed J 2010; 14: 77-82.
47. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol 2012; 181: 1903-10.
48. Victor N, Ivy A, Jiang BH, Agani FH. Involvement of HIF-1 in invasion of Mum2B uveal melanoma cells. Clin Exp Metastasis 2006; 23: 87-96.
49. MacLeod RJ, Hayes M, Pacheco I. Wnt5a secretion stimulated by the extracellular calcium-sensing receptor inhibits defective Wnt signaling in colon cancer cells. Am J Physiol Gastrointest Liver Physiol 2007; 293: G403-11.
50. Conrad WH, Swift RD, Biechele TL, Kulikauskas RM, Moon RT, Chien AJ. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS-and BRAF-mutant melanoma cells with Wnt/beta-catenin activation. Cell Cycle 2012; 11: 3724-30.
51. Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. J Vis Exp 2011; 54: e2937.